Oxalo Therapeutics

Oxalo Therapeutics is committed to developing first-class therapies for the treatment and prevention of diseases caused by hyperoxaluria and hyperoxalemia. We are a preclinical-stage biopharmaceutical company leveraging our expertise in the microbiome, translational research, and early technology commercialization to deliver innovative therapies. The needs of our patients and cutting-edge research are the catalysts driving the growth of our company. Based on groundbreaking discoveries in gut microbiota, Oxalo’s approach mimics a natural mechanism that safely removes oxalate from the body, thereby preventing the recurrence of kidney stones and other oxalate-related diseases.